PMID: 8968423Jan 1, 1996Paper

Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors

Advances in Neuroimmunology
E OberholtzerL Matera

Abstract

Our previous studies have shown that prolactin (PRL), a pituitary and lymphocyte hormone and a ligand of the cytokine/hemopoietin receptors (R) superfamily, acts synergistically with interleukin (IL)-2 on the development of lymphokine activated killer (LAK) cells and enhances the effects of GM-CSF and IL-3 on myeloid progenitors' proliferation and differentiation. More recently, we have demonstrated that GM-CSF and IL-3 increase the sensitivity of acute myeloid leukemic (AML) cells to LAK activity. Together, these findings have prompted us to study the role of PRL on the target arm of the LAK response. We show here that CD33+ blasts from AML patients express membrane PRL-R and that the PRL/PRL-R interaction is followed by increased susceptibility to natural killer (NK) (p < 0.02) and LAK (p < 0.001) cells. As predicted from the dimerization model of PRL-R and in agreement with previous reports, the response of AML blasts to PRL was bell-shaped with a trend peak at 25 ng/ml. Although enhanced lysis occurred at the target recognition level, it was not accompanied by changes in the MHC class I, cellular adhesion molecules, or myeloid differentiation antigens. Cell cycle recruitment and lysis increased concurrently in three cases s...Continue Reading

References

Nov 1, 1978·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·J FriedB D Clarkson
Aug 1, 1992·Immunology Today·L MorettaK Kärre
Jun 1, 1991·Immunology Today·A N AkbarG Janossy
Aug 1, 1991·Endocrine Reviews·P A KellyM Edery
Apr 1, 1991·Journal of Cellular Biochemistry·E A Grimm, L Owen-Schaub
Aug 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·C V ClevengerM B Prystowsky
Jul 1, 1990·Immunology Today·H G Ljunggren, K Kärre
Apr 1, 1990·The International Journal of Neuroscience·L MateraF Veglia
Apr 1, 1989·British Journal of Haematology·E Nagy, I Berczi
Jan 1, 1989·Advances in Immunology·G Trinchieri
Mar 1, 1988·Brain, Behavior, and Immunity·L MateraE Genazzani
Jan 1, 1981·European Journal of Immunology·M HanssonB Andersson
Jun 1, 1995·Current Opinion in Immunology·G M Griffiths
Apr 1, 1994·Current Opinion in Cell Biology·N Sato, A Miyajima
Feb 1, 1996·Current Opinion in Immunology·M Colonna

❮ Previous
Next ❯

Citations

Sep 2, 2000·Journal of Neuroimmunology·L MateraG Palestro
Jan 15, 2000·Journal of Neuroimmunology·S Basu, P S Dasgupta
Jan 6, 2000·Molecular Pathology : MP·A J WoodP G Murray
Oct 12, 2000·Journal of Neuroimmunology·R KooijmanE L Hooghe-Peters
Oct 11, 2012·Critical Reviews in Biochemistry and Molecular Biology·Mariya Atanasova, Adrian Whitty

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.